PAYMENT FORM

FEES FOR TYPE IA VARIATIONS, TYPE IA
VARIATIONS DESCRIBING THE GROUP, TYPE
IA VARIATIONS INCLUDED INTO THE
GROUP, TYPE IB VARIATIONS, TYPE IB
VARIATIONS DESCRIBING THE GROUP, TYPE
IB VARIATIONS INCLUDED INTO THE
GROUP, TYPE II VARIATIONS, TYPE II
VARIATIONS DESCRIBING THE GROUP, TYPE
II VARIATIONS INCLUDED INTO THE GROUP,
TRANSFER OF MARKETING
AUTHORISATION AND OTHER CHANGES TO
MARKETING AUTHORISATION THROUGH
NATIONAL PROCEDURE

Pharmaceutical form, strength, administration route Pharmaceutical form: Strength: Administration route: Marketing authorisation holder Name: Address: City: Country: Phone no.: Fax no.: E-mail no.:	Medicinal product name						
Pharmaceutical form: Strength: Administration route: Marketing authorisation holder Name: Address: City: Country: Phone no.: Fax no.:							
Pharmaceutical form: Strength: Administration route: Marketing authorisation holder Name: Address: City: Country: Phone no.: Fax no.:							
Pharmaceutical form: Strength: Administration route: Marketing authorisation holder Name: Address: City: Country: Phone no.: Fax no.:							
Strength: Administration route: Marketing authorisation holder Name: Address: City: Country: Phone no.: Fax no.:	Pharmaceutic	cal form,	strength, administration route				
Strength: Administration route: Marketing authorisation holder Name: Address: City: Country: Phone no.: Fax no.:	Di	-1.6	Г				
Marketing authorisation holder Name: Address: City: Country: Phone no.: Fax no.:		al form:					
Marketing authorisation holder Name: Address: City: Country: Phone no.: Fax no.:							
Name: Address: City: Country: Phone no.: Fax no.:	Administration	route:					
Name: Address: City: Country: Phone no.: Fax no.:							
Address: City: Country: Phone no.: Fax no.:	Marketing au	thorisatio	on holder				
Address: City: Country: Phone no.: Fax no.:	Nicos						
City: Country: Phone no.: Fax no.:							
Country: Phone no.: Fax no.:							
Phone no.: Fax no.:							
Fax no.:							
E-mail no. :							
	E-mail no. :						

Medicinal product status		
MA no/date of issue Please specify if currently under MA renewal procedure, if applicable.		
Paying company		
Name: Address:		
City:		
Country: Phone no.:		
Fax no.:		
E-mail no. :		
Fiscal code		
No. with the Register of Trade		
IBAN account :		
BanK:		
Proposal for payment		
Lei:		
Euro:		
Service paid*		
		Amount of tariff in euro according to MHO no. 888/2014**
Assessment of application for type IA variations and type IA variations describing the	ype/ number of ons)	

Assessment of application for type IB variations and type IB variations describing the group Assessment of application for type II variations and type II variations and type II variations describing the group Assessment of application for type IA included into the group Assessment of application for type IB included into the group Assessment of application for type IB included into the group Assessment of application for type II variations) Assessment of application for type II included into the group Assessment of application for transfer of marketing authorisation Assessment of application for changes to design and labelling of medicinal products for human use as well as for changes to leaflet and Summary of Products characteristics, other than those derived from type IA, IB and II variations, according to	group				
application for type II variations and type II variations and type II variations describing the group Assessment of application for type IA included into the group Assessment of application for type IB included into the group Assessment of application for type II included into the group Assessment of application for type II included into the group Assessment of application for transfer of marketing authorisation Assessment of application for changes to design and labelling of medicinal products for human use as well as for changes to leaflet and Summary of Products characteristics, other than those derived from type IA, IB and II	Assessment of application for type IB variations and type IB variations describing the	` • •	number	of	
application for type IA included into the group Assessment of application for type IB included into the group Assessment of application for type II included into the group Assessment of application for type II included into the group Assessment of application for transfer of marketing authorisation Assessment of application for changes to design and labelling of medicinal products for human use as well as for changes to leaflet and Summary of Products characteristics, other than those derived from type IA, IB and II	application for type II variations and type II variations describing the		number	of	
application for type IB included into the group Assessment of application for type II included into the group Assessment of application for transfer of marketing authorisation Assessment of application for changes to design and labelling of medicinal products for human use as well as for changes to leaflet and Summary of Products characteristics, other than those derived from type IA, IB and II	application for type IA	\ , ,	number	of	
application for type II included into the group Assessment of application for transfer of marketing authorisation Assessment of application for changes to design and labelling of medicinal products for human use as well as for changes to leaflet and Summary of Products characteristics, other than those derived from type IA, IB and II	application for type IB	` • •	number	of	
application for transfer of marketing authorisation Assessment of application for changes to design and labelling of medicinal products for human use as well as for changes to leaflet and Summary of Products characteristics, other than those derived from type IA, IB and II	application for type II	` • •	number	of	
application for changes to design and labelling of medicinal products for human use as well as for changes to leaflet and Summary of Products characteristics, other than those derived from type IA, IB and II	application for transfer of				
Minister of Health Order	application for changes to design and labelling of medicinal products for human use as well as for changes to leaflet and Summary of Products characteristics, other than those derived from type IA, IB and II variations, according to				

^{*} the service will be tariffed per strength of the medicinal product/ pharmaceutical form of the medicinal product
** the applicant will fill in the fee in euro currency

Name :	
Adress:	
City:	
Country:	
Phone no.:	
Fax no.:	
E-mail:	

Representative office in Romania/ Contact person

The undersigned take all responsibility on the accuracy of the data in this form.
Date

Marketing authorisation holder/ Representative office in Romania Name, signature, stamp